For the glioma subpopulation characterized by IDH-wild-type status, high MCT4 expression, and a high lactate burden, it is recommended that the pharmacodynamic chain—wherein lactate reduction leads to increased pH and subsequent immune activation—be validated in the preoperative window. The gene discussed is SLC16A3; the disease is glioma.